3
H index
0
i10 index
15
Citations
Office of Health Economics | 3 H index 0 i10 index 15 Citations RESEARCH PRODUCTION: 8 Articles 13 Papers RESEARCH ACTIVITY:
EXPERT IN:
MORE DETAILS IN: ABOUT THIS REPORT:
|
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Christopher James Sampson. | Is cited by: | Cites to: |
| Journals with more than one article published | # docs |
|---|---|
| PharmacoEconomics - Open | 2 |
| Working Papers Series with more than one paper published | # docs |
|---|---|
| Contract Research / Office of Health Economics | 6 |
| MPRA Paper / University Library of Munich, Germany | 3 |
| Grant-Funded Research / Office of Health Economics | 2 |
| Briefing / Office of Health Economics | 2 |
| Year | Title of citing document |
|---|---|
| 2026 | Departures from health universalism? A value set of AP-7D in Japan as an attempt to develop a “culture-specific” preference-based measure. (2026). Norman, Richard ; Luo, Nan ; Hoshino, Eri ; Rowen, Donna ; Mulhern, Brendan ; Morii, Yasuhiro ; Murata, Tatsunori ; Shiroiwa, Takeru ; Fukuda, Takashi. In: Social Science & Medicine. RePEc:eee:socmed:v:393:y:2026:i:c:s0277953626000973. Full description at Econpapers || Download paper |
| 2025 | Transparency and Accountability of NGOs in Managing Corporate Social Funds. (2025). Gustomo, Aurik ; Rorimpandey, Samuel Stephan. In: European Journal of Business and Management Research. RePEc:epw:ejbmr0:v:10:y:2025:i:3:id:52325. Full description at Econpapers || Download paper |
| Year | Title | Type | Cited |
|---|---|---|---|
| 2024 | Marginal cost per QALY estimates: What are they good for? In: Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2019 | How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefing. [Citation analysis] | paper | 3 |
| 2021 | How is Quality of Life Measured for Health Technology Assessments? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
| 2018 | Barriers to Uptake of Minimal Access Surgery in the United Kingdom In: Contract Research. [Full Text][Citation analysis] | paper | 0 |
| 2018 | The Impact of New Medicines in the NHS: 70 Years of Innovation In: Contract Research. [Full Text][Citation analysis] | paper | 0 |
| 2023 | The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe In: Contract Research. [Full Text][Citation analysis] | paper | 0 |
| 2024 | A Framework for Value-aligned Pricing of Combination Therapies In: Contract Research. [Full Text][Citation analysis] | paper | 0 |
| 2025 | The value of cell and gene therapies to the UK economy In: Contract Research. [Full Text][Citation analysis] | paper | 0 |
| 2026 | The impact of inflation on incremental costs in HTA In: Contract Research. [Full Text][Citation analysis] | paper | 0 |
| 2018 | R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Grant-Funded Research. [Full Text][Citation analysis] | paper | 1 |
| 2020 | Drop Dead: Is Anchoring at ‘Dead’ a Theoretical Requirement in Health State Valuation? In: Grant-Funded Research. [Full Text][Citation analysis] | paper | 0 |
| 2013 | Cost implications of treatment non-completion in a forensic personality disorder service In: MPRA Paper. [Full Text][Citation analysis] | paper | 0 |
| 2013 | Happy and healthy: a joint model of health and life satisfaction In: MPRA Paper. [Full Text][Citation analysis] | paper | 0 |
| 2013 | The relationship between individual risk and cost-effectiveness in screening interventions In: MPRA Paper. [Full Text][Citation analysis] | paper | 0 |
| 2021 | Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al. In: Medical Decision Making. [Full Text][Citation analysis] | article | 1 |
| 2022 | Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 0 |
| 2013 | Do patients registered with CAM-trained GPs really use fewer health care resources and live longer? A response to Kooreman and Baars. Eur J Health Econ (2012). 13:469–776 In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 0 |
| 2019 | Transparency in Decision Modelling: What, Why, Who and How? In: PharmacoEconomics. [Full Text][Citation analysis] | article | 5 |
| 2017 | Model Registration: A Call to Action In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 4 |
| 2022 | NICE and the EQ-5D-5L: Ten Years Trouble In: PharmacoEconomics - Open. [Full Text][Citation analysis] | article | 0 |
| 2024 | Is anchoring at ‘dead’ a theoretical requirement for health state valuation? In: Health Economics. [Full Text][Citation analysis] | article | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Last updated August, 20 2026. Contact: CitEc Team